Skip Navigation U.S. Department of Health and Human Services www.hhs.gov/
Agency for Healthcare Research Quality www.ahrq.gov
www.ahrq.gov/

Treating Tobacco Use and Dependence: Slide Presentation (Full Set)


Treatment Recommendations: Medications (Continued)

Text Description is below the image.

Meta-analysis (2008): Effectiveness and abstinence rates for various medications and medication combinations compared to placebo at 6-months post-quit (n = 86 studies)

Medication Number of arms Estimated odds ratio (95% C.I.) Estimated abstinence rate (95% C.I.)
Placebo 80 1.0 13.8
Monotherapies      
Varenicline (2 mg/day) 5 3.1 (2.5, 3.8) 33.2 (28.9, 37.8)
Nicotine Nasal Spray 4 2.3 (1.7, 3.0) 26.7 (21.5, 32.7)
High Dose Nicotine Patch (> 25 mg) (These included both standard or long-term duration) 4 2.3 (1.7, 3.0) 26.5 (21.3, 32.5)
Long-Term Nicotine Gum (> 14 weeks) 6 2.2 (1.5, 3.2) 26.1 (19.7, 33.6)
Varenicline (1 mg/day) 3 2.1 (1.5, 3.0) 25.4 (19.6, 32.2)
Nicotine Inhaler 6 2.1 (1.5, 2.9) 24.8 (19.1, 31.6)
Clonidine 3 2.1 (1.2, 3.7) 25.0 (15.7, 37.3)

Next SlidePrevious Slide        Contents         Next Slide Next Slide


 

AHRQAdvancing Excellence in Health Care